Background: Alcoholism is a chronic relapsing disorder with complex behavioral and functional heterogeneity. To date, attempts to characterize subgroups of alcohol-dependent (AD) individuals have largely been focused on categorical distinctions based on behaviors such as ability to abstain, age of onset, and drinking motives, but these have failed to yield predictors of treatment response and disease course. The distinction between AD individuals who are or are not interested in treatment holds significant implications for interpreting results of human laboratory studies with nontreatment seekers and clinical trials with treatment-seeking AD patients. However, despite their crucial role in alcohol-related research, these 2 groups are poorly defined. In this exploratory analysis, we attempt to better define the phenotypic differences between these 2 experimentally relevant populations.
A LCOHOL DEPENDENCE (AD) as defined by criteria in the Diagnostic and Statistical Manual of Mental Disorders (DSM), fourth edition, is a chronic relapsing disorder and a costly public health problem with a lifetime prevalence of 30.3% in the United States (Hasin et al., 2007) . Alcohol use disorder as defined in DSM-5 has a comparable lifetime prevalence of 29.1% . Similar to other psychiatric illnesses such as depression, anxiety, and psychosis, AD is a complex condition with tremendous behavioral and functional heterogeneity. Attempts to refine the classification of AD patients have largely been focused on categorical distinctions based on behaviors such as the ability to abstain, age of onset, and motives for drinking. These approaches have failed to yield well-defined predictors of treatment response and disease course (Boschloo et al., 2012; Leggio et al., 2009; Moos and Moos, 2006) . Defining, more precisely, individual behavioral differences within the AD population will aid in identifying effective treatments that may be matched to specific subgroups of AD individuals.
An important but poorly understood feature of AD is the difference in characteristics between those who seek treatment compared to those who do not seek treatment for AD. Notably, only 8.4% of those with AD ever receive treatment (Substance Abuse and Mental Health Services Administration, 2014). The reasons for this are complex and stem from manifold societal and individual factors (Xu et al., 2008) . According to the Health Belief Model (Bardsley and Beckman, 1988 ) and stress and coping models (Finney and Moos, 1995) , important factors in the decision to seek treatment for addiction are more severe consequences of drinking and greater perceived severity of the illness; in addition, individuals with addiction who present to the criminal justice system are often court-mandated to treatment. Opposing these are barriers to seeking treatment such as resistance to reduce drinking, cost, stigma, and accessibility of treatment (Andr easson et al., 2013; Substance Abuse and Mental Health Services Administration, 2009; Xu et al., 2008) . Epidemiological research, conducted largely in community cohorts, has identified factors associated with treatment-seeking behavior in AD individuals: older age, male sex, nonwhite race, as well as unemployed or unmarried status (Weisner, 1993) . The relationship between social consequences and engagement in treatment is mixed, with studies finding positive, negative, or no influence on treatment entry (Finney and Moos, 1995; Weisner, 1993; Weisner and Matzger, 2002) . Impaired memory and executive function are also associated with reduced motivation for treatment in AD individuals (Le Berre et al., 2012) .
In contrast to community treatment settings for AD, research settings for AD are unique in that both treatmentand nontreatment-seeking AD subjects participate in clinical studies. Nontreatment-seeking individuals with AD are often recruited for participation in early-stage studies that evaluate a potential therapeutic drug for AD for safety and tolerability when given in combination with alcohol. These studies involve alcohol administration paradigms where the effect of an experimental drug to reduce alcohol craving and selfadministration is also measured. If promising, further larger clinical trials are conducted in the treatment-seeking AD population (Litten et al., 2016) . Given this, the characteristics of these 2 groups are important to understand to evaluate potential therapeutic strategies, both psychosocial and pharmacologic. In particular, it is important to know whether the nontreatment-seeking group has distinct characteristics that might independently affect study outcome measures, thereby creating a confound in this field of clinical research.
Accordingly, in this study, we sought to compare psychological and physiological characteristics of treatment-seeking versus nontreatment-seeking AD individuals among participants interested in participating in alcohol-related research studies. We sought to identify underlying characteristic differences within our research population to characterize the individual variability across these 2 experimentally and clinically relevant groups.
MATERIALS AND METHODS

Participants
Data were analyzed from 3 protocols at the National Institute on Alcohol Abuse and Alcoholism (NIAAA) implemented to screen treatment-and nontreatment-seeking AD research participants from 2008 to 2015. Participants were recruited through word of mouth, community outreach, the National Institutes of Health (NIH) website, as well as online and newspaper advertisements. Subject preference to receive treatment or not was determined through a phone screen. A healthcare practitioner later confirmed the treatment-or nontreatment-seeking status at the time of the inperson outpatient visit (for nontreatment-seeking subjects) or inpatient admission (for the treatment-seeking subjects). These protocols were approved by the NIH Institutional Review Board, and individuals gave written informed consent before participating. Only participants who met criteria for AD were included in this study (n = 791). Among them, 615 were treatment seekers and 176 were nontreatment seekers. Participants were not simultaneously in both groups.
Screening Measures
As part of these screening protocols, both treatment-and nontreatment-seeking participants underwent a large battery of medical, psychological, and psychiatric tests. Broadly, the measures fell into the following categories: personality, impulsivity, trauma/ stress, drinking, cognition, aggression, and mood. These measures consisted of continuous and categorical variables with scales that varied from yes/no questions to Likert-scale responses. These measures were chosen by NIAAA investigators to give a comprehensive assessment of neuropsychological factors related to AD, general health, as well as to determine suitability for other research protocols.
The Structured Clinical Interview for DSM Disorders (First et al., 2002) was conducted to assess psychiatric as well as alcohol and substance use disorders (DSM-IV). DSM-IV criteria were parsed into 2 groups. One contained the AD criteria that reflect the positive reinforcing effect of drinking: tolerance and drinking more than planned; the other contained criteria associated with the negative effects of AD: unsuccessful attempts to cut down, missed activities because of drinking, psychological problems because of drinking, and withdrawal symptoms. Group differences in the number of criteria endorsed in each of these 2 categories as well as the total number of AD criteria endorsed were assessed. Family history density of AD was also measured using the Family Tree Questionnaire (Mann et al., 1985) . Recent alcohol use was assessed using a Timeline Follow Back questionnaire (Sobell and Sobell, 1996) .
Subjects also underwent assessments of cognitive ability (Wechsler Abbreviated Scale of Intelligence; Wechsler, 1999) , mood (Comprehensive Psychopathological Rating Scale; Mattila-Evenden et al., 1996) , impulsivity (Barratt Impulsivity Scale [BIS]; Patton et al., 1995 and UPPS-P Impulsive Behavior Scale; Lynam et al., 2006) , personality (Neuroticism-Extraversion-Openness; Costa and McCrae, 1997) , aggression (Buss-Perry Aggression Questionnaire; Buss and Perry, 1992) , and early-life stress/trauma (Early Life Stress Questionnaire; McFarlane et al., 2005 and Childhood Trauma Questionnaire; Bernstein et al., 2003) .
Standard clinical laboratory biomarkers conducted at the NIH Clinical Center included a hepatic panel (alanine aminotransferase [ALT]; aspartate aminotransferase [AST]; alkaline phosphatase, gamma-glutamyl transferase [GGT]), a mineral panel (calcium, magnesium, phosphorus, potassium, and sodium), albumin, hemoglobin, mean corpuscular volume (MCV), hepatitis B antigen, and hepatitis C antibody.
Analysis
For continuous measures, means, standard deviations (SDs), and 95% confidence intervals (CIs) are presented for each group. Group differences were tested for significance via independent samples t-tests (if normally distributed) or independent samples Mann-Whitney U-tests (if nonnormally distributed). Normality was tested by the Shapiro-Wilk Test. For categorical measures, frequencies and prevalence rates are presented; group differences were tested for significance via Pearson's chi-square test (or Fisher's exact tests). Odd ratios (ORs) and 95% CIs were obtained for dichotomous measures via logistic regression.
To determine whether alcohol consumption accounted for group differences, all models were rerun with drinks per drinking day included as covariate. In the case for continuous measures, analysis of covariance (ANCOVA) and rank analysis of covariance (Quade, 1967) were used for normally and nonnormally distributed measures, respectively. For dichotomous variables, logistic regression was used.
For all statistical tests, p < 0.05 (2-tailed) was considered statistically significant. As this is an exploratory analysis, no adjustments were made for multiple tests. Data were analyzed using SPSS (IBM© SPSS© version 20; Armonk, NY).
RESULTS
Group Differences in Demographics
Treatment seekers, as compared to nontreatment seekers, were more likely to be women and Caucasian (Table 1 ). The groups did not different significantly by age.
Group Differences in Behavioral and Neuropsychological Measures
Group differences on the behavioral and neuropsychological measures are shown in Table 2 . As each of these measures was not normally distributed, group differences were tested using the Mann-Whitney U-test. Treatment seekers reported drinking significantly more total alcohol drinks, drinks per drinking day, and heavy drinking days. Treatment seekers, compared to nontreatment seekers, scored significantly higher on measures of personality (neuroticism and conscientiousness), impulsivity (almost every subscale of the BIS and UPPS-P), and trauma/stress (early-life stress events, childhood emotional abuse, and physical neglect). They also scored significantly higher on aggression and endorsed more symptoms of depression and anxiety. Treatment seekers also had significantly higher IQ and scored higher on measures cognitive complexity and cognitive instability.
After covarying for drinking behavior, 18 of 26 of the neuropsychiatric measures remained significantly different between groups with the same direction of difference. Two group differences emerged on measures of physical aggression (Nontreatment > Treatment) and years of education (Treatment > Nontreatment) ( Table 2) .
Group Differences in DSM-IV Criteria for AD
In addition to endorsing significantly greater number of total AD criteria, mean (SD): 5.70 (1.61) versus 4.51 (1.39); F (1, 757) = 75.13, p < 0.001, treatment seekers endorsed more negative reinforcing AD criteria compared to nontreatment seekers (Table 2 ). There was no group difference in the number of positive reinforcing criteria endorsed. The group differences in number of total AD criteria and negative dependence criteria remained significant after average drinks per drinking day was used as a covariate. In addition, there were group differences in the individual criteria endorsed: Unsuccessful attempts to cut down on drinking, spending much time in drinking, missing activities because of drinking, psychological problems because of drinking, and withdrawal were more frequently endorsed in treatment seekers compared to nontreatment seekers (Table 3) .
Group Differences in Blood Biomarkers
Significant group differences in liver enzyme tests (ALT, AST, and GGT) clinically used as biomarkers of alcohol use were observed (Table 2) , with treatment seekers having higher levels for each as compared to nontreatment seekers. Notably, group differences in these persisted after controlling for drinking behavior. Statistically significant group differences were also found for hemoglobin, MCV, iron, albumin, and sodium, but both groups fell within the "normal" range, thereby suggesting that this variability was not clinically relevant (data not shown). No group differences were observed for the prevalence of serum hepatitis B surface antigen or hepatitis C antibody. NEO-PI-R, Neuroticism-Extraversion-Openness; UPPS-P, UPPS-P Impulsive Behavior Scale [(negative) Urgency, (lack of) Premeditation, (lack of) Perseverance, Sensation Seeking]; CTQ, Childhood Trauma Questionnaire; ELSQ, Early Life Stress Questionnaire; TLFB, Timeline Follow Back; WASI, Wechsler Abbreviated Scale of Intelligence; BPAQ, Buss-Perry Aggression Questionnaire; CPRS, Comprehensive Psychopathological Rating Scale; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase.
Items underlined and bolded were significant after controlling for average drinks per drinking day; physical aggression and years of education became significant after covarying for drinking (p = 0.002 and p = 0.006, respectively).
DISCUSSION
This exploratory study examined differences between treatment-seeking and nontreatment-seeking AD research participants who were characterized with a comprehensive battery of behavioral, neuropsychological, and clinical measures as well as diagnostic (DSM-IV) criteria. These results are relevant to designing and interpreting results from clinical research studies of AD individuals. An exploratory approach applied to a large number of neurobehavioral measures identified categories where multiple measures therein were significantly different between groups. The categories were measures related to: alcohol drinking, personality, impulsivity, trauma/stress, cognition, and mood. In general, the treatment-seeking group showed more severe behaviors in several of the measures included in each of these categories. When compared based on their desire to engage in treatment, these 2 groups diverge with respect to their scores in diverse domains and remain divergent after controlling for drinking behavior.
With respect to DSM-IV criteria, predictably, treatmentseeking participants endorsed more dependence criteria and preferentially endorsed the criteria related to negative consequences of use. Indeed, perceived severity of the illness is an important factor in treatment entry (Bardsley and Beckman, 1988) . In line with this, treatment seekers endorsed more severe drinking patterns and this was supported by correspondingly higher levels of liver-related blood biomarkers of alcohol use in the treatment seekers. That said, covarying for average drinks per drinking day removed neither significant group differences in DSM-IV AD criteria nor group differences in these biomarkers, suggesting that some other biobehavioral aspect of their drinking behavior is responsible for this group difference.
There were also group differences in family history of AD. This observation also suggests potential influence from genetic or environmental factors impacting treatment-seeking status. This is consistent with previous work, including twin studies and prospective cohort studies, which have indicated that genetic and shared environmental influences account for approximately 40% of the variance in help seeking for alcohol problems (True et al., 1997) , family history of AD is associated with help seeking and higher healthcare utilization, and a history of help seeking for alcohol problems among family members of offspring is associated with the offspring's own alcohol problem recognition (Glass et al., 2015; Milne et al., 2009; True et al., 1999) .
Beyond drinking patterns and traditional DSM-IV AD criteria, this in-depth characterization of this population of AD individuals across multiple neurobehavioral domains allows for identification of subdomains that allow for more detailed characterization of those who do and do not seek treatment for AD. This can inform approaches to AD treatment. Previous studies (Kessler et al., 2001; Weisner, 1993; Weisner and Matzger, 2002) indicate that aggression or a history of stress and trauma leads to more drinking-related problems, comorbidity, and thus engagement in treatment. In each category of characterization measures, there were several measures that were significantly different and the majority of these significant differences remained after controlling for average drinks per drinking day. This suggests that these 2 populations with the same diagnosis differ in ways that cannot be attributed to alcohol consumption itself. Significantly, greater depression and anxiety in treatment seekers highlight the psychological heterogeneity of this AD population as do the differences in early-life stress events and physical neglect scores, which all remained significantly different after covarying for drinking behavior. Similarly, the treatment-seeking group is more impulsive and hostile, again, regardless of the quantity of alcohol consumed.
These measures, therefore, may represent separate targets for behavioral and/or pharmacologic intervention that are focused on directly remediating, for example, impulsivity, aggression, depression, and anxiety. Addressing these in combination, with interventions that reduce drinking such as behavioral (e.g., motivational interviewing) and/or pharmacotherapy treatments, may improve outcomes for subsets of patients with impairments in these domains. For treatment seekers, this approach to identify subgroups of AD individuals has also been used to predict response to pharmacologic treatments based on other (i.e., genetic variation) endophenotypes (for reviews, see Kenna, 2010; Kranzler and McKay, 2012) . Identifying factors associated with not seeking treatment provides an opportunity to define a population at risk and intervene before drinking progresses. For nontreatment seekers, the results of this study indicate that the absence of several DSM-IV criteria (Table 3 ) and the presence of either tolerance or endorsing drinking more than planned are significantly associated with not seeking treatment. In addition, confidence intervals (95%) for each measure shown in Table 2 provide a guide for categorizing patients into 1 of the 2 groups. Obviously, defining the nontreatment-seeking group presents an opportunity to intervene in this population, perhaps with motivational interviewing that focuses on entities such as loss of control over drinking to prevent progression to increasingly severe AD.
Neurobehavioral differences between treatment and nontreatment seekers are also relevant as they may be confounding factors in AD treatment research. Experimental outcomes in pharmacotherapy clinical trials may be influenced by characteristics of the study population itself. Early efficacy proof-of-concept human laboratory studies of putative treatments are often carried out with nontreatment-seeking individuals, especially if alcohol administration procedures take place (Enoch et al., 2009 ). The characteristics of the nontreatment-seeking individuals, which we report here diverge from treatment seekers, might directly affect the outcome measures themselves presenting a confound for studies that evaluate potential treatments for AD. Results from these studies may not translate to the treatment-seeking population. For example, it is possible that factors such as impulsivity, aggression, and mood independently affect outcomes in human laboratory studies that measure craving, physiological tone in response to alcohol cues, and the decision to drink at the expense of monetary reward (Plebani et al., 2012; Ray et al., 2010) . Treatments thought ineffective based on results from studies in nontreatment seekers in proof-of-concept human laboratory studies may be prematurely rejected before proceeding to larger clinical trials with treatment seekers. As such, it is valuable to characterize AD subjects beyond DSM-IV criteria and self-reported drinking behavior.
Results of this study explore categories that significantly differ between treatment-and nontreatment-seeking AD research participants. These results provide novel neurobehavioral-based information and are a first step to understanding in a more refined way the characteristics of this research population of AD individuals. Further study of the categories identified here might help to explain variance in clinical trial outcomes.
This study has several limitations. The study was exploratory; therefore, multiple uncorrected tests were conducted. Our approach is consistent with Bender and Lange (2001) who suggested that exploratory analyses be carried out without multiplicity adjustment but confirmed in follow-up studies. As such, a separate sample will be necessary to confirm the present findings. For the 64 group comparisons conducted, one would expect 3 to be significant by chance alone.
We report 38 significant group comparisons (including biomarkers with statistically significant though not clinically significant group differences). No attempt was made to covary for factors other than drinking behavior that might affect the individual outcomes, such as age of onset of AD. The fact that in each category, multiple measures were significantly different and remained different when alcohol consumption was taken into account indicates that these categories provide a basis for further work to characterize the heterogeneity of this complex population with AD. The sample was also relatively small and not equally balanced between the 2 groups. The fact that participants were compensated for participation may have affected their performance on certain measures. Also, compensation levels may have varied between subjects in both groups due to each person's time spent involved in research procedures. We also did not have follow-up data to determine whether phenotypic differences were predictive of relapse in the treatment seekers. Importantly, those who participate in alcohol research protocols, both treatment and nontreatment seekers, are not necessarily reflective of the corresponding groups in the general population. While future analyses will require larger samples and advanced analytic approaches, the present findings hold significant importance as they illustrate the utility of better characterizing relevant clinical and research phenotypes using broad behavioral and neuropsychological measures.
In conclusion, this study provides novel information on neurobehavioral phenotypes that distinguish between individuals who seek, or do not seek, treatment for AD, in a research setting. It is clear that the diagnosis of AD comprises large phenotypic variation and we have presented data on phenotypic differences in 2 clinically relevant subgroups of AD individuals. Understanding how these 2 groups differ especially beyond drinking behavior is vital to refining clinical research in AD, especially given that current research on AD treatment often depends on translating results obtained in the nontreatment-seeking population to treatment seekers.
